Title:
NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/080780
Kind Code:
A1
Abstract:
The present invention relates to an indazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing, treating, or ameliorating cancer, comprising, as an active ingredient, the derivative or a pharmaceutically acceptable salt thereof. The indazole derivative of the present invention is designed to provide strong binding to the C-terminal domain of Hsp90, and does not affect the composite structure of Hsp90 and HSF-1, thus not inducing the activation of HSF-1 or the expression of Hsp genes, thereby effectively promoting apoptosis of cancer cells. Thus, the indazole derivative of the present invention can be used in the prevention, treatment, or amelioration of cancer.
More Like This:
Inventors:
SEO JAE HONG (KR)
KIM JI YOUNG (KR)
KIM YOON JAE (KR)
PARK MINSU (KR)
SEO JUYEON (KR)
KO DONGMI (KR)
KIM SEONGJAE (KR)
PARK SOEUN (KR)
LEE JEEWOO (KR)
ANN JI HYAE (KR)
HOANG VAN-HAI (KR)
LA MINH THANH (KR)
KIM JI YOUNG (KR)
KIM YOON JAE (KR)
PARK MINSU (KR)
SEO JUYEON (KR)
KO DONGMI (KR)
KIM SEONGJAE (KR)
PARK SOEUN (KR)
LEE JEEWOO (KR)
ANN JI HYAE (KR)
HOANG VAN-HAI (KR)
LA MINH THANH (KR)
Application Number:
PCT/KR2023/015723
Publication Date:
April 18, 2024
Filing Date:
October 12, 2023
Export Citation:
Assignee:
KOREA UNIV RESEARCH AND BUSINESS FOUNDATION (KR)
SEOUL NATIONAL UNIV R&DB FOUNDATION (KR)
SEOUL NATIONAL UNIV R&DB FOUNDATION (KR)
International Classes:
C07D405/12; A61K31/416; A61K31/454; A61K31/496; A61K31/5377; A61P35/00; C07D401/06; C07D401/14; C07D405/14
Attorney, Agent or Firm:
MUHANN PATENT & LAW FIRM (KR)
Download PDF: